An independent quality assurance program has been established by the Division of AIDS, National Institute of Allergy and Infectious Diseases, for monitoring virologic assays performed by nearly 40 laboratories participating in multicenter clinical trials in the United States. Since virologic endpoints are important in evaluating the timing and efficacy of therapeutic interventions, it is imperative that virologic measurements be accurate and uniform. When the quality assurance program was initially created, fewer than 40%o of the laboratories could consistently recover human immunodeficiency virus (HIV) from peripheral blood mononuclear cells (PBMCs) of HIVinfected patients. By comparing coculture procedures in the more competent laboratories with those in laboratories who were struggling to isolate virus, optimal conditions were established and nonessential reagents and practices were eliminated. Changes were rapidly introduced into a laboratory when experience dictated that such modifications would result in a favorable outcome. Isolation of HIV was enhanced by optimizing the numbers and ratios of patient and donor cells used in cultures, by standardizing PBMC separation procedures, by using fresh rather than frozen donor PBMCs, by processing whole blood within 24 h, and by using natural delectinated interleukin 2 instead of recombinant interleukin 2 products in existence at that time. Delays of more than 8 h in the addition of phytohemagglutinin-stimulated donor cells to freshly separated patient PBMCs reduced recovery. Phytohemagglutinin in cocultures and the addition of Polybrene and anti-human alpha interferon to media were not important in HIV isolation. The introduction of a consensus protocol based on this information brought most laboratories quickly into compliance. In addition, monthly monitoring has successfully maintained proficiency among the laboratories, a process that is critical for the scientific integrity of collaborative multicenter trials. Problems which might not be appreciated for months are now being resolved early, before data can be compromised unknowingly. This consensus protocol is recommended for any laboratory attempting to isolate HIV for the purpose of standardizing recovery and for accessing virologic endpoints in clinical trials.
Removal of plasma from centrifuged whole blood (200 x g for 10 min at 20 to 24°C) prior to processing PBMCs also does not appear to affect recovery. About half of the 11 reference laboratories elected to do this because it provided a plasma sample for other studies. All but 6 of the 24 centers diluted the remaining whole blood from 1:2 to 1:3 prior to processing, with the vast majority using a 1:2 dilution. When this option was selected, plasma removal proceeded prior to dilution of the residual blood sample. The diluent employed did not appear to be important unless citrate-phosphatedextrose or acid-citrate-dextrose was used, in which case a calcium-free diluent was essential to avoid clot formation.
Most of the centers used phosphate-buffered saline (PBS) or a balanced salt solution (without calcium). Two of the reference laboratories used saline. The brand of lymphocyte separation solution (LSS) used also did not appear to be important. Among the reference laboratories, four used LSS from Organon, five used LSS from Pharmacia, and two used LSS from Sigma.
Recovery of PBMCs from the LSS gradient must be optimized to ensure that an adequate number of cells are obtained for coculture. Thus, conditions of time, temperature, g force, and volume of LSS and blood used must be standardized. As much as a 10-fold difference in cell recovery was observed among the various laboratories when comparable samples of blood were processed. Superior recovery was observed when a ratio of 4 parts blood was layered over 3 parts LSS, e.g., 16 ml of undiluted or diluted blood to 12 ml of LSS. However, up to three times more blood than LSS is acceptable. Most laboratories used a 50-ml conical centrifuge tube for sedimenting their cells. Six reference laboratories centrifuged the blood at 24 to 26°C, three used 20 to 21°C, and one used 37°C. The g force and time selected for centrifugation also were quite variable. To achieve standardization, 30 min at 400 x g and 20 to 24°C was selected. Following removal of the PBMCs at the gradient-plasma (or diluent) interface, the cells were washed. The number of washes did not appear to be critical. Although it is recommended that donor PBMCs be cultured separately to confirm seronegativity, no laboratory has reported such an occurrence.
All laboratories but one used RPMI 1640 medium containing glutamine and 10 to 20% heat-inactivated fetal bovine serum. In addition, all laboratories stimulated their donor cells with phytohemagglutinin (PHA-P), usually purchased from Difco or Sigma. This purified plant lectin provides the stimulus for initiating a proliferative T-cell response (10) through the generation of interleukin 2 (IL-2) receptors and the synthesis of IL-2 (3, 9, 14). The median and mode PHA-P concentration used by the reference laboratories was 5 ,ug/ml (range, 0.2 to 50 ,ug/ml). High concentrations of PHA-P were clearly detrimental. Nine of the 11 2.5 ,ug/ml (median, 1.25 ,ug/ml). While no specific detrimental effect on virus recovery was observed at these facilities, the use of an antifungal agent is not recommended, since HIV expression may be inhibited, resulting in a false-negative response if the virus burden is low (8, 11, 15 (17, 21) .
In contrast to the superfluous role of PHA-P in the coculture medium, IL-2 is an essential ingredient. As previously stated, the use of natural, delectinated IL-2 at a 5% concentration appeared to enhance HIV recovery, whereas isolation rates were substantially reduced when recombinant IL-2 was used. Only 5 of 11 reference laboratories used Polybrene (1 to 10 ,ug/ml, with a mode of 2 ,ug/ml), and only 2 of 11 used anti-human alpha interferon (0.4 to 200 U/ml) in the cocultivation medium. Thus, as noted above, these two products did not appear to be necessary for HIV recovery.
Either penicillin (100 U/ml)-streptomycin (100 p.g/ml) or gentamicin (50 pg/ml) was added to the medium at the concentrations described above. Only one reference laboratory added amphotericin B (1.25 p.g/ml) to the PBMC coculture medium.
The total number of patient PBMCs in each coculture ranged from 6 x 106 to 120 x 10' cells, with a median of 10 x 106 PBMCs. The Centrifuge anticoagulated blood at 200 x g for 10 minutes at 20 to 240C and remove most of the plasma which should be aliquoted and frozen. 2.
To one part centrifuged blood, from which most of the plasma has been removed, add one part diluent (saline or PBS) e.g., 8 mL centrifuged blood to 8 mL diluent.
3. Layer 4 parts of diluted blood over 3 parts lymphocyte separation solution (LSS: Organon or Pharmacia) e.g., 16 mL diluted blood over 12 mL LSS.
4.
Centrifuge at 400 x g for 30 minutes at 20 to 24°C. Remove PBMCs and wash twice in two volumes of PBS or Hanks BSS.
5.
Enumerate cells and adjust sample with culture medium to achieve a concentration of 2 million cells per mL.
B.
Stimulation of Donor PBMCs
1.
Stimulation Medium for donor PBMCs:
a.
RPMI 1640 with glutamine; 20% fetal bovine serum (heat-inactivated); PHA-P (5 ttg/mL, Difco or Sigma); 3% IL-2 (Cellular Products, Electro-Nucleonics, or Boehringer Mannheim); penicillin (100 units/mL)/streptomycin (100 t1g/mL) or gentamicin (50 sg/mL).
2.
IL-2 should be a purified, delectinated human preparation, not a recombinant product. Amphotericin B should be avoided as it may inhibit HIV replication.
3.
Do not use frozen donor cells or pooled donor PBMCs.
4.
Process random donor buffy coats within 12 hours of collection.
5.
Maximum PBMC concentration in stimulation culture: 2 million PBMCs/mL. 6.
Use only anti-HIV negative donors; culture donor PBMCs separately to verify absence of HIV infectivity. RPMI 1640 with glutamine; 20% fetal bovine serum (heat-inactivated); 5% natural, delectinated IL-2; penicillin/streptomycin or gentamicin (concentrations cited above).
2.
Coculture patient PBMCs within 8 hours of processing.
3.
Sediment I to 3 day old stimulated donor PBMCs at 200 x g for 10 minutes at 20 to 24°C, remove and discard supernatant, then resuspend cells in coculture medium and enumerate cells. Adjust sample with coculture medium to a concentration of 2 million PBMCs/mL.
4.
Maintain equivalent concentrations of donor PBMCs to patient PBMCs e.g., 10 million donor cells to 10 million patient cells in 10 mL medium (final PBMC concentration: 2 million PBMCs/mL).
5.
Remove one-half volume of coculture medium every 3 to 4 days and replace with an equal volume of fresh medium. The medium is saved at -30°C to -80°C for HIV p24 antigen determination.
6.
Once a week add 10 million, freshly pelleted and enumerated, 1 to 3 day old PHAstimulated donor cells (2 million PBMCs/mL), resuspended in coculture medium.
D.
Assaying Medium for HIV (p24) Antigen to Determine HIV Replication I. Fresh or frozen medium may be tested and clarification is optional. by centrifugation does not appear to affect the overall assay recovery of virus in cocultures. Centrifugation parameters results.
and volume of lymphocyte separation medium employed in Consensus protocol. As a direct result of the questionnaire, processing whole blood were standardized. Delays of up to which was supplemented by an analysis of culture data from PHA-P and IL-2. Correspondingly, fresh PHA-stimulated donor cells should be added weekly to the cocultures. We also found that frozen cells and recombinant IL-2 products commercially available at the time of this study should not be used in cocultures, that Polybrene and anti-human alpha interferon were not essential, and that the use of antifungal agents in the medium should be discouraged. Equivalent concentrations of donor and patient PBMCs were recommended for the coculture procedure, and medium requirements were similar to those needed to maintain donor cells except that PHA-P was not essential. Data showed that recovery of virus was substantially reduced if the addition of PHA-stimulated donor cells to freshly processed patient cells was delayed for more than 8 h.
On the basis of this information, a consensus protocol for HIV isolation by coculture was formulated (Fig. 2) . The protocol was validated at the VRL, which found no significant difference in the days-to-first-positive results obtained for HIV-infected patient samples tested using both its existing HIV coculture system and the consensus protocol (data not shown). The method was then distributed to all the participating ACTG virology laboratories. This consensus protocol is recommended for any laboratory attempting to (ii) Certification of laboratories. Until September 1990, all ACTG laboratories were evaluated monthly. A certification round consisted of QA coculture results from a 3-or 4-month evaluation period. The correct positive or negative result for each HIV QA coculture was based on an 80% consensus agreement among the reference laboratories (laboratories that had been certified for the three most recent consecutive certification periods). The positive or negative result, as well as the days to first positive, was identified for each culture by using the HIV p24 antigen criteria outlined above. Subsequently, a numeric score, based on a point system listed in Table 2 virology laboratories successfully isolated HIV from each of six infected blood samples! Five other laboratories had an acceptable rate of recovery (>80%), but the interval to first positive response often was inordinately delayed, and three of these laboratories failed to isolate virus from one of the samples. The performance of eight other laboratories was less than satisfactory. Four were unable to detect virus in two of the six samples, and two laboratories recovered virus in only two samples. This initial evaluation emphasized the desperate need for a QA program designed to achieve consistent and optimal levels of isolation so that a more quantitative approach could eventually be developed. 
